References
- Fernandes, G. F. D. S.; Chin, C. M.; Santos, J. L. D. Advances in drug discovery of new antitubercular multidrug-resistant compounds. Pharmaceuticals 2017, 10, 51. DOI: https://doi.org/10.3390/ph10020051.
- Joule, J. A. Natural products containing nitrogen heterocycles some highlights 1990-2015. Adv. Heterocycl. Chem. 2016, 119, 81–106. DOI: https://doi.org/10.1016/bs.aihch.2015.10.005.
- Sharma, V.; Chitranshi, N.; Agarwal, A. K. Significance and biological importance of pyrimidine in the microbial world. Int. J. Med. Chem. 2014, 2014, 202784. DOI: https://doi.org/10.1155/2014/202784.
- Ramsey, S. J.; Attkins, N. J.; Fish, R.; Graaf, P. H. V. D. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. Br. J. Pharmacol. 2011, 164, 992–1007. DOI: https://doi.org/10.1111/j.1476-5381.2011.01390.x.
- Al-Adiwish, W. M.; Tahir, M. I. M.; Siti-Noor-Adnalizawati, A.; Hashim, S. F.; Ibrahim, N.; Yaacob, W. A. Synthesis, antibacterial activity and cytotoxicity of new fused pyrazolo[1,5-a]pyrimidine and pyrazolo[5,1-c][1,2,4]triazine derivatives from new 5-aminopyrazoles. Eur. J. Med. Chem. 2013, 64, 464–476. DOI: https://doi.org/10.1016/j.ejmech.2013.04.029.
- Braendvang, M.; Gundersen, L. L. Synthesis, biological activity, and SAR of antimycobacterial 2- and 8-substituted 6-(2-furyl)-9-(p-methoxybenzyl)purines. Bioorg. Med. Chem. 2007, 15, 7144–7165. DOI: https://doi.org/10.1016/j.bmc.2007.07.034.
- Ugwu, D. I.; Ezema, B. E.; Eze, F. U.; Ugwuja, D. I. Synthesis and structural activity relationship study of antitubercular carboxamides. Int. J. Med. Chem. 2014, 2014, 614808–614818. DOI: https://doi.org/10.1155/2014/614808.
- Bahuguna, A.; Rawat, D. S. An overview of new antitubercular drugs, drug candidates, and their targets. Med. Res. Rev. 2020, 40, 263–292. DOI: https://doi.org/10.1002/med.21602.
- Maliyappa, M. J.; Keshavayya, J.; Mallikarjuna, N. M.; Pushpavathi, I. Novel substituted aniline based heterocyclic dispersed azo dyes coupling with 5- methyl-2-(6-methyl-1, 3-benzothiazol-2-yl)-2, 4-dihydro-3h-pyrazol-3-one: Synthesis, structural, computational and biological studies. J. Mol. Struct. 2020, 1205, 127576. DOI: https://doi.org/10.1016/j.molstruc.2019.127576.
- Palomino, J. C.; Martin, A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel) 2014, 3, 317–340. DOI: https://doi.org/10.3390/antibiotics3030317.
- Caminero, J. A.; Sotgiu, G.; Zumla, A.; Migliori, G. B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 2010, 10, 621–629. DOI: https://doi.org/10.1016/S1473-3099(10)70139-0.
- Ballell, L.; Field, R. A.; Duncan, K.; Young, R. J. New small-molecule synthetic antimycobacterials. Antimicrob. Agents Chemother . 2005, 49, 2153–2163. DOI:10.1128/AAC.49.6.2153–2163.2005.
- Dover, L. G.; Coxon, G. D. Current status and research strategies in tuberculosis drug development. J. Med. Chem. 2011, 54, 6157–6165. DOI: https://doi.org/10.1021/jm200305q.
- Pepper, O. J.; Marais, S.; Wilkinson, R. J.; Bhaijee, F.; Maartens, G.; McIlleron, H.; Azevedo, V. D.; Helen Cox, M.; Dermid, C.; Sokhela, S.; Patel, D.; et al. Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. BMC. Infect. Dis. 2010, 10, 1. DOI: https://doi.org/10.1186/1471-2334-10-83.
- Joule, J. A. Natural products containing nitrogen heterocycles—some highlights 1990–2015. Adv. Heterocycl. Chem. 2016. 119, 81–106. DOI: https://doi.org/10.1016/bs.aihch.2015.10.005.
- Moreira, R. R. D.; Martins, G. Z.; Pietro, R. C. L. R.; Sato, D. N.; Pavan, F. R.; Leite, S. R. A.; Vilegas, W.; Leite, C. Q. F. Antimycobacterial activity of extracts, methoxylated flavonoids and naphthopyranone fractions. Rev. Brasil. Farmacognosia 2013, 23, 268–272. DOI: https://doi.org/10.1590/S0102-695X2012005000137.
- Nagaraja, O.; Bodke, Y. D.; Kenchappa, R.; Ravi Kumar, S. Synthesis and characterization of 3-[3-(1h-benzimidazol-2-ylsulfanyl)-3-phenyl propanoyl]-2H-chromen-2-one derivatives as potential biological agents. Chem. Data. Collect. 2020, 27, 100369. DOI: https://doi.org/10.1016/j.cdc.2020.100369.
- Luckner, S. R.; Liu, N.; Ende, C. W. A.; Tonge, P. J.; Kisker, C. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J. Biol. Chem. 2010, 285, 14330–14337. DOI: https://doi.org/10.1074/jbc.M109.090373.